{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:52:17Z","timestamp":1790527937398,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["522002003"],"award-info":[{"award-number":["522002003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007192","name":"Rijksinstituut voor Volksgezondheid en Milieu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO\u2010NL\u2010276\u20104222"],"award-info":[{"award-number":["CO\u2010NL\u2010276\u20104222"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO\u2010US\u2010276\u20101712"],"award-info":[{"award-number":["CO\u2010US\u2010276\u20101712"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007553","name":"Aids Fonds","doi-asserted-by":"publisher","award":["2013169"],"award-info":[{"award-number":["2013169"]}],"id":[{"id":"10.13039\/100007553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["PA\u2010HIV\u2010PREP\u201016\u20100024"],"award-info":[{"award-number":["PA\u2010HIV\u2010PREP\u201016\u20100024"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["PHNL\/JAN\/0714\/0005b\/1912fde"],"award-info":[{"award-number":["PHNL\/JAN\/0714\/0005b\/1912fde"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["3000268822"],"award-info":[{"award-number":["3000268822"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["3000747780"],"award-info":[{"award-number":["3000747780"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern AIDS Soc"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Amsterdam Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> project is a prospective, open\u2010label demonstration study at a large sexually transmitted infection (<jats:styled-content style=\"fixed-case\">STI<\/jats:styled-content>) clinic. We examined the uptake of Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>; the baseline characteristics of men who have sex with men (<jats:styled-content style=\"fixed-case\">MSM<\/jats:styled-content>) and transgender persons initiating Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>; their choices of daily <jats:italic>versus<\/jats:italic> event\u2010driven Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> and the determinants of these choices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From August 2015 through May 2016, enrolment took place at the <jats:styled-content style=\"fixed-case\">STI<\/jats:styled-content> clinic of the Public Health Service of Amsterdam, the Netherlands. <jats:styled-content style=\"fixed-case\">MSM<\/jats:styled-content> or transgender persons were eligible if they had at least one risk factor for <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection within the preceding six months. Participants were offered a choice between daily or event\u2010driven use of tenofovir\/emtricitabine. Baseline data were analysed using descriptive statistics and multivariable analysis was employed to determine variables associated with daily <jats:italic>versus<\/jats:italic> event\u2010driven Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Online applications were submitted by 870 persons, of whom 587 were invited for a screening visit. Of them, 415 were screened for eligibility and 376 initiated Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>. One quarter (103\/376, 27%) chose event\u2010driven Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>. Prevalence of bacterial <jats:styled-content style=\"fixed-case\">STI<\/jats:styled-content> was 19.0% and mean condomless anal sex (<jats:styled-content style=\"fixed-case\">CAS<\/jats:styled-content>) episodes in the preceding three months were 11. In multivariable analysis, older age (\u226545 <jats:italic>vs<\/jats:italic>. \u226434, <jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content> 2.1, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.2 to 3.9), being involved in a steady relationship (<jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content> 1.7, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.0 to 2.7), no other daily medication use (<jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content> 0.6, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.3 to 0.9), and fewer episodes of <jats:styled-content style=\"fixed-case\">CAS<\/jats:styled-content> (per log increase <jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content> 0.7, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.6 to 0.9) were determinants for choosing event\u2010driven PrEP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> programmes are becoming one of the more important intervention strategies with the goal of reducing incident <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infection and we were unable to accommodate many of the persons applying for this study. Offering a choice of dosing regimen to Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> users may enable further personalization of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> prevention strategies and enhance up\u2010take, adherence and cost\u2010effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The majority of participants preferred daily <jats:italic>versus<\/jats:italic> event\u2010driven use. Within this majority, a high number of <jats:styled-content style=\"fixed-case\">CAS<\/jats:styled-content> episodes before Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> initiation was reported and we observed a high prevalence of <jats:styled-content style=\"fixed-case\">STI<\/jats:styled-content>. Determinants of choosing event\u2010driven Pr<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> were older age, fewer <jats:styled-content style=\"fixed-case\">CAS<\/jats:styled-content> episodes, no other daily medication use, and involved in a steady relationship.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.25105","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T23:37:34Z","timestamp":1522971454000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Men who have sex with men more often chose daily than event\u2010driven use of pre\u2010exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam"],"prefix":"10.1002","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-2109","authenticated-orcid":false,"given":"Elske","family":"Hoornenborg","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Research and Prevention Public Health Service of Amsterdam Amsterdam the Netherlands"},{"name":"Department of Infectious Diseases Public Health Service of Amsterdam STI Outpatient Clinic Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel CA","family":"Achterbergh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Public Health Service of Amsterdam STI Outpatient Clinic Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F Schim","family":"van der Loeff","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Research and Prevention Public Health Service of Amsterdam Amsterdam the Netherlands"},{"name":"Department of Infectious Diseases Academic Medical Center Center for Immunity and Infection Amsterdam (CINIMA) University of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi","family":"Davidovich","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Research and Prevention Public Health Service of Amsterdam Amsterdam the Netherlands"},{"name":"Department of Infectious Diseases Academic Medical Center Center for Immunity and Infection Amsterdam (CINIMA) University of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannie J","family":"van der Helm","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Research and Prevention Public Health Service of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Hogewoning","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Public Health Service of Amsterdam STI Outpatient Clinic Amsterdam the Netherlands"},{"name":"Department of Dermatology Academic Medical Center University of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne THP","family":"van Duijnhoven","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Public Health Service of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard JB","family":"Sonder","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Communicable Diseases Control Public Health Service of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry JC","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Public Health Service of Amsterdam STI Outpatient Clinic Amsterdam the Netherlands"},{"name":"Department of Dermatology Academic Medical Center University of Amsterdam Amsterdam the Netherlands"},{"name":"National Institute of Public Health and the Environment Center for Infectious Disease Control Bilthoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Research and Prevention Public Health Service of Amsterdam Amsterdam the Netherlands"},{"name":"Department of Infectious Diseases Academic Medical Center Center for Immunity and Infection Amsterdam (CINIMA) University of Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"VanSighem ABS WitF SmitC MatserA ReissP.Monitoring report 2016. Human immunodeficiency Virus (HIV) Infection in the Netherlands.Amsterdam: Stichting HIV monitoring;2016. [cited 2017 Nov 6]. Available from:wwwhiv\u2010monitoringnl"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_2_8_5_1","unstructured":"MolinaJM.One\u2010year experience with pre\u2010exposure prophylaxis (PrEP) in France with TDF\/FTC. Presented at IAS2017 abstract WEPEC0939."},{"key":"e_1_2_8_6_1","unstructured":"Centers for Disease Control and Prevention.Recommendations for HIV prevention with adults and adolescents with HIV in the United States. [cited 2017 Nov 6]. Available from:https:\/\/stackscdcgov\/view\/cdc\/260622014"},{"key":"e_1_2_8_7_1","unstructured":"World Health Organization.Guideline on when to start antiretroviral therapy and on pre\u2010exposure prophylaxis for HIV.2015. [cited 2017 Nov 6]. Available from:http:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en\/"},{"key":"e_1_2_8_8_1","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM).French PrEP protocol. [cited 2017 Nov 6]. Available from:http:\/\/ansmsantefr\/content\/download\/89337\/1123645\/version\/1\/file\/RTU_Truvada_Protocole_Juin-2016pdf2016"},{"key":"e_1_2_8_9_1","unstructured":"European AIDS Clinincal Society (EACS).European Guidelines for treatment of HIV\u2010positive adults in Europe; Guidelines 9.0. [cited 2017 Nov 6]. Available from:http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html"},{"key":"e_1_2_8_10_1","unstructured":"European Centre for Disease Prevention and Control.Evidence brief: Pre\u2010exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC. [cited 2017 Nov 6]. Available from:https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/pre-exposure-prophylaxis-hiv-prevention-europe.pdf"},{"issue":"25","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"30263","DOI":"10.2807\/1560-7917.ES.2016.21.25.30263","volume":"21","author":"Noori T","year":"2016","journal-title":"Euro Surveill"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/964512"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30311-5"},{"key":"e_1_2_8_14_1","unstructured":"AMPrEP study group.Study protocol AMPrEP.2015. [cited 2017 June 14]. Available from:http:\/\/www.trialregister.nl\/trialreg\/admin\/rctsearch.asp?Term=amprep"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000187054"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001522"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2015-052052"},{"issue":"4","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s10508-009-9483-9","article-title":"Sexual compulsivity and sexual risk in gay and bisexual men","volume":"39","author":"Grov C","year":"2010","journal-title":"Arch Sex Behav"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-10"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"e_1_2_8_21_1","first-page":"2001","volume-title":"The alcohol use disorders identification test: guideline for use in primary care","author":"Babor TF","year":"2001"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081413"},{"issue":"3","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1207\/s15327752jpa6203_1","article-title":"Sexual sensation seeking: scale development and predicting AIDS\u2010risk behavior among homosexually active men","volume":"62","author":"Kalichman SC","year":"1994","journal-title":"J Pers Assess"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10720160127562"},{"issue":"8","key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/QAD.0000000000000639","article-title":"What do Dutch MSM think of preexposure prophylaxis to prevent HIV\u2010infection? A cross\u2010sectional study","volume":"29","author":"Bil JP","year":"2015","journal-title":"AIDS"},{"issue":"39","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"e4910","DOI":"10.1097\/MD.0000000000004910","article-title":"Motives of Dutch men who have sex with men for daily and intermittent HIV pre\u2010exposure prophylaxis usage and preferences for implementation: A qualitative study","volume":"95","author":"Bil JP","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_8_27_1","unstructured":"CoyerL VanBilsen W BilJ DavidovichU HoornenborgE PrinsM et\u00a0al.Pre\u2010exposure prophylaxis (PrEP) among men who have sex with men (MSM) in the Amsterdam Cohort Studies (ACS): Eligibility intention and actual use. Presented at the Netherlands Conference of HIV 2017.Amsterdam the Netherlands. Abstract number O15.2017."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001627"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001129"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1286-4"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3182515601"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416651229"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.082271"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70847-3"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.4683"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60833-3"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2016.1154085"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjia2.25105","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:52:21Z","timestamp":1695516741000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/jia2.25105"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25105","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"2017-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25105"}}